Suscribirse

Troponin Elevations After Electroconvulsive Therapy: The Need for Caution - 19/08/11

Doi : 10.1016/j.amjmed.2010.09.023 
Matthew W. Martinez, MD a, Keith G. Rasmussen, MD b, Paul S. Mueller, MD c, Allan S. Jaffe, MD a, d,
a Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minn 
b Department of Psychiatry, Mayo Clinic, Rochester, Minn 
c Division of General Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minn 
d Core Clinical Laboratory Services Division, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minn 

Requests for reprints should be addressed to Allan S. Jaffe, MD, Division of Cardiovascular Diseases, Mayo Clinic, 200 First Street SW, Rochester, MN 55905

Abstract

Background

Electroconvulsive therapy is used to treat patients with severe or resistant depression. Troponin elevations are associated with an adverse prognosis, and it is well known that central nervous system insults can cause biochemical evidence of cardiac injury. No study previously has studied this with electroconvulsive therapy.

Methods

Patients scheduled for electroconvulsive therapy were enrolled. Clinical information, an electrocardiogram, and a baseline sample for cardiac troponin I and T (cTnI and cTnT) were obtained. Electroconvulsive therapy was done with standard techniques. Subsequently, electrocardiograms and additional samples were obtained. cTnT was measured with the Roche assay and cTnI with the Dade Stratus equipment. Values above the 99th percentile were considered abnormal.

Results

Seventy patients completed the study. Four patients had elevated levels of cTn before treatment. In 3 patients, the elevations persisted. Four additional patients developed elevated cTn levels during electroconvulsive therapy. Two of the patients with cTn elevations died. No other events occurred during follow-up.

Conclusions

Elevations of cTn occurred in 11.5% of patients treated with electroconvulsive therapy. Some of the elevations preceded therapy and some occurred during treatment. Given the adverse prognostic importance of cTn elevations in general, in addition to additional studies, an increased degree of medical scrutiny may be appropriate for this group of patients and for those receiving electroconvulsive therapy. © 2011 Elsevier Inc. All rights reserved.

El texto completo de este artículo está disponible en PDF.

Keywords : Electroconvulsive therapy, Troponin


Esquema


 Funding: Supported in part by the small grants program through the Division of Cardiology at the Mayo Clinic, Rochester, Minnesota.
 Conflict of Interest: Dr. Jaffe is at present or has been in the past a consultant to most of the major diagnostic companies, including those that make the troponin assays used in this study.
 Authorship: All authors had access to the data and played a role in writing this manuscript.
 Dr. Matthew W. Martinez is now at the Lehigh Valley Health Network, 1250 S Cedar Crest Blvd., Suite 300, Allentown, PA 18103.


© 2011  Elsevier Inc. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 124 - N° 3

P. 229-234 - mars 2011 Regresar al número
Artículo precedente Artículo precedente
  • Medical Bankruptcy in Massachusetts: Has Health Reform Made a Difference?
  • David U. Himmelstein, Deborah Thorne, Steffie Woolhandler
| Artículo siguiente Artículo siguiente
  • Patterns and Correlates of Prostate Cancer Treatment in Older Men
  • Calpurnyia B. Roberts, Peter C. Albertsen, Yu-Hsuan Shao, Dirk F. Moore, Amit R. Mehta, Mark N. Stein, Grace L. Lu-Yao

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.